Evidence map›Paper›PMID 41951974›Full record

ArticleNature microbiology2026

A penicillin-binding protein inhibitor series to target drug-resistant Neisseria gonorrhoeae.

Tsuyoshi Uehara, Allison L Zulli, Brittany Miller, Lindsay M Avery, Steven A Boyd, Cassandra L Chatwin, Guo-Hua Chu, Anthony S Drager, Mitchell Edwards, Susan G Emeigh Hart and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Tsuyoshi UeharaVenatorx Pharmaceuticals, Inc., Malvern, PA, USA. tsuyoshi.uehara@gmail.com.ORCID http://orcid.org/0000-0001-6994-4286
Allison L Zulli *Venatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Brittany Miller *Venatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Lindsay M AveryVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Steven A BoydVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.ORCID http://orcid.org/0000-0002-8460-2310
Cassandra L ChatwinVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Guo-Hua ChuVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Anthony S DragerVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Mitchell EdwardsVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Susan G Emeigh HartVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Nathan J LineVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Cullen L MyersVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Gopinath RongalaVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.ORCID http://orcid.org/0000-0001-9459-648X
Annie StevensonVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.ORCID http://orcid.org/0009-0009-0737-3209
Kyoko UeharaVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Fan YiVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.ORCID http://orcid.org/0000-0003-4717-8167
Bibo WangBioDuro-Sundia, Beijing, China.
Zhenwu LiuBioDuro-Sundia, Beijing, China.
Mingyue WangBioDuro-Sundia, Beijing, China.
Zhichao ZhaoBioDuro-Sundia, Beijing, China.
Xinming ZhouBioDuro-Sundia, Beijing, China.
Haiyan ZhaoBioDuro-Sundia, Beijing, China.
Caleb M StrattonDepartment of Biochemistry and Molecular Biology, University of South Alabama, Mobile, AL, USA.ORCID http://orcid.org/0000-0001-7955-795X
Sandeepchowdary BalaDepartment of Biochemistry and Molecular Biology, University of South Alabama, Mobile, AL, USA.
Christopher DaviesDepartment of Biochemistry and Molecular Biology, University of South Alabama, Mobile, AL, USA.
Rok TkavcHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Ann E JerseDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-5118-3172
Daniel C PevearVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Christopher J BurnsVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Denis M DaigleVenatorx Pharmaceuticals, Inc., Malvern, PA, USA.
Stephen M CondonVenatorx Pharmaceuticals, Inc., Malvern, PA, USA. stephencondon3418@gmail.com.ORCID http://orcid.org/0009-0008-8536-4378

Funding

New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeaeR01AI141239 · NIAID · VENATORX PHARMACEUTICALS, INC. · PI DAIGLE, DENIS MARC · 2019 to 2023
$7.5M
Molecular mechanism of cephalosporin resistance of N. gonorrhoeae conferred by mutated PBP2R01AI164794 · NIAID · UNIVERSITY OF SOUTH ALABAMA · PI Christopher Davies · 2022 to 2026
$3.5M
NIAID NIH HHS R01 AI141239NIAID NIH HHS R01 AI164794
6 · The paper itself

Abstract

Emerging multidrug-resistant Neisseria gonorrhoeae strains possessing altered penA alleles (encoding penicillin-binding protein 2, PBP2) threaten the utility of ceftriaxone, the last remaining outpatient antibiotic for gonorrhoea treatment, posing a global health emergency. Here we report a benzoxaborinine-based penicillin-binding protein inhibitor series (boro-PBPi) developed to address penA-mediated ceftriaxone resistance. Optimization of boro-PBPi led to the identification of compound 21 (VNRX-14079), which exhibited potent antibacterial activity against multidrug-resistant N. gonorrhoeae through high-affinity binding to the PBP2 target. Boro-PBPi-PBP2 complex structures confirmed the covalent interaction of the boron atom with the catalytic residue Ser310 and the importance of the β

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialNeisseria gonorrhoeaePenicillin-Binding ProteinsAnimalsBoron CompoundsCeftriaxoneFemaleGonorrheaHumansMiceMicrobial Sensitivity TestsSerine-Type D-Ala-D-Ala CarboxypeptidaseAnti-Bacterial AgentsBoron CompoundsCeftriaxonepenicillin-binding protein 2, Neisseria gonorrhoeaePenicillin-Binding ProteinsSerine-Type D-Ala-D-Ala Carboxypeptidase

Identifiers

PMID41951974
PMCPMC13171604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.